Non-competitive androgen receptor inhibition in vitro and in vivo
- 28 April 2009
- journal article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 106 (17), 7233-7238
- https://doi.org/10.1073/pnas.0807282106
Abstract
Androgen receptor (AR) inhibitors are used to treat multiple human diseases, including hirsutism, benign prostatic hypertrophy, and prostate cancer, but all available anti-androgens target only ligand binding, either by reduction of available hormone or by competitive antagonism. New strategies are needed, and could have an important impact on therapy. One approach could be to target other cellular mechanisms required for receptor activation. In prior work, we used a cell-based assay of AR conformation change to identify non-ligand inhibitors of AR activity. Here, we characterize 2 compounds identified in this screen: pyrvinium pamoate, a Food and Drug Administration-approved drug, and harmol hydrochloride, a natural product. Each compound functions by a unique, non-competitive mechanism and synergizes with competitive antagonists to disrupt AR activity. Harmol blocks DNA occupancy by AR, whereas pyrvinium does not. Pyrvinium inhibits AR-dependent gene expression in the prostate gland in vivo, and induces prostate atrophy. These results highlight new therapeutic strategies to inhibit AR activity.Keywords
This publication has 32 references indexed in Scilit:
- A Cellular Conformation-Based Screen for Androgen Receptor InhibitorsACS Chemical Biology, 2008
- Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT CorepressorsCancer Research, 2007
- Cell- and gene-specific regulation of primary target genes by the androgen receptorGenes & Development, 2007
- The Small Molecule Harmine Is an Antidiabetic Cell-Type-Specific Regulator of PPARγ ExpressionCell Metabolism, 2007
- Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling AxisJournal of Clinical Oncology, 2005
- Molecular determinants of resistance to antiandrogen therapyNature Medicine, 2003
- Hsp90 as a therapeutic target in prostate cancerSeminars in Oncology, 2003
- Genotoxic effects of structurally related β-carboline alkaloidsMutation Research - Reviews in Mutation Research, 1997
- Two Androgen Response Regions Cooperate in Steroid Hormone Regulated Activity of the Prostate-specific Antigen PromoterPublished by Elsevier BV ,1996
- Isolation and characterization of androgen-dependent non-histone chromosomal protein from dorsolateral prostate of ratsBiochemical and Biophysical Research Communications, 1982